🇺🇸 FDA
Pipeline program

ORMD-0801 8 mg

ORA-D-013-3

Phase 3 small_molecule active

Quick answer

ORMD-0801 8 mg for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at ORAMED PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ORAMED PHARMACEUTICALS INC.
Indication
Type 2 Diabetes Mellitus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials